Does Rallies show Form 4 insider transactions for CNTA?

Yes. Rallies tracks CNTA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CNTA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CNTA. It does not provide personalized investment advice.

CNTA (Centessa Pharmaceuticals plc American Depositary Shares) Stock Analysis - Insider Trades

Centessa Pharmaceuticals plc American Depositary Shares (CNTA) is a publicly traded Healthcare sector company. As of May 20, 2026, CNTA trades at $39.55 with a market cap of $6.13B and a P/E ratio of -27.22. CNTA moved +0.18% today. Year to date, CNTA is +72.68%; over the trailing twelve months it is +201.14%. Its 52-week range spans $9.60 to $40.26. Analyst consensus is neutral with an average price target of $42.40. Rallies surfaces CNTA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CNTA stock inside the company?

Recent CNTA insider activity includes Anderson Karen M. sold 41.08K, Weinhoff Gregory M sold 24.00K, Anderson Karen M. sold 10.04K, Anderson Karen M. sold 64.77K, and Anderson Karen M. sold 107.96K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CNTA Key Metrics

Key financial metrics for CNTA
Metric	Value
Price	$39.55
Market Cap	$6.13B
P/E Ratio	-27.22
EPS	$-1.46
Dividend Yield	0.00%
52-Week High	$40.26
52-Week Low	$9.60
Volume	814.63K
Avg Volume	0
Revenue (TTM)	$15.00M
Net Income	$-197.53M
Gross Margin	0.00%

Recent CNTA Insider Trades

Anderson Karen M. sold 41.08K (~$1.24M) on Mar 26, 2026.
Weinhoff Gregory M sold 24.00K (~$719.94K) on Mar 26, 2026.
Anderson Karen M. sold 10.04K (~$282.21K) on Mar 17, 2026.
Anderson Karen M. sold 64.77K (~$1.83M) on Mar 16, 2026.
Anderson Karen M. sold 107.96K (~$2.82M) on Mar 13, 2026.

Latest CNTA News

Law Firm Challenges Centessa $38 Cash Plus Up to $9 CVR Sale to Lilly — May 12, 2026
Eli Lilly to Acquire Centessa for $7.8B Including $38 Cash, $9 CVRs — Apr 2, 2026
Centessa Pharmaceuticals Shares Soar 44.4% to $39.90 on $6.3B Eli Lilly Deal — Mar 31, 2026
Eli Lilly to Acquire Centessa for $38 per Share, Up to $7.8B — Mar 31, 2026

CNTA Analyst Consensus

10 analysts cover CNTA: 0 strong buy, 1 buy, 9 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $42.40.

Common questions about CNTA

Who is trading CNTA stock inside the company?: Recent CNTA insider activity includes Anderson Karen M. sold 41.08K, Weinhoff Gregory M sold 24.00K, Anderson Karen M. sold 10.04K, Anderson Karen M. sold 64.77K, and Anderson Karen M. sold 107.96K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CNTA?: Yes. Rallies tracks CNTA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CNTA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CNTA. It does not provide personalized investment advice.